Repligen (NASDAQ:RGEN) Stock Falls 6.4% – Here’s Why

Repligen Corporation (NASDAQ:RGEN) shares fell 6.4% on Thursday. The company traded as low as $180.05 and last traded at $179.9820. Approximately 656,256 shares were traded during mid-day trading, a decline of 36% from the average session volume of 1,020,536 shares. The stock had previously closed at $192.23.

Analyst Ratings Changes

A number of research analysts have recently commented on RGEN shares. HSBC dropped their price target on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a research note on Wednesday, June 3rd. Citigroup upgraded shares of Repligen to a “buy” rating in a research report on Tuesday, July 7th. Wells Fargo & Company lifted their target price on Repligen from $180.00 to $185.00 and gave the stock an “overweight” rating in a report on Thursday, July 30th. Zacks Research lowered shares of Repligen from a “strong-buy” rating to a “hold” rating in a report on Monday. Finally, Benchmark raised shares of Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a research report on Tuesday, July 7th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $168.57.

Repligen Price Performance

The business’s fifty day moving average is $168.59 and its 200-day moving average is $140.59. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The firm has a market cap of $10.15 billion, a PE ratio of 246.26, a P/E/G ratio of 3.55 and a beta of 1.05.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The firm had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. During the same period in the previous year, the company earned $0.26 earnings per share. The company’s quarterly revenue was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, research analysts predict that Repligen Corporation will post 2.06 earnings per share for the current fiscal year.

Institutional Trading of Repligen

Hedge funds have recently made changes to their positions in the company. ABS Investment Management LLC bought a new stake in Repligen in the 2nd quarter valued at about $191,016,000. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Repligen in the second quarter valued at approximately $52,000. Trust Co. of Vermont purchased a new stake in shares of Repligen during the 2nd quarter valued at approximately $71,000. Harbor Investment Advisory LLC lifted its stake in shares of Repligen by 198.9% during the 2nd quarter. Harbor Investment Advisory LLC now owns 523 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 348 shares in the last quarter. Finally, Allworth Financial LP purchased a new position in Repligen in the 2nd quarter valued at approximately $71,000. 97.64% of the stock is currently owned by institutional investors.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and supplies bioprocessing technologies used by biopharmaceutical manufacturers to produce biological drugs, including monoclonal antibodies, recombinant proteins, vaccines and cell and gene therapies. Its products are used throughout the manufacturing process, from laboratory and process development through commercial-scale production.

The company’s portfolio includes chromatography products and protein A ligands and resins, filtration and fluid-management systems, single-use technologies, process analytics and other consumables and equipment.